BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 34990866)

  • 1. Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma.
    Porsbjerg CM; Menzies-Gow AN; Tran TN; Murray RB; Unni B; Audrey Ang SL; Alacqua M; Al-Ahmad M; Al-Lehebi R; Altraja A; Belevskiy AS; Björnsdóttir US; Bourdin A; Busby J; Canonica GW; Christoff GC; Cosio BG; Costello RW; FitzGerald JM; Fonseca JA; Hansen S; Heaney LG; Heffler E; Hew M; Iwanaga T; Jackson DJ; Kocks JWH; Kallieri M; Bruce Ko HK; Koh MS; Larenas-Linnemann D; Lehtimäki LA; Loukides S; Lugogo N; Maspero J; Papaioannou AI; Perez-de-Llano L; Pitrez PM; Popov TA; Rasmussen LM; Rhee CK; Sadatsafavi M; Schmid J; Siddiqui S; Taillé C; Taube C; Torres-Duque CA; Ulrik C; Upham JW; Wang E; Wechsler ME; Bulathsinhala L; Carter V; Chaudhry I; Eleangovan N; Hosseini N; Rowlands MA; Price DB; van Boven JFM
    J Allergy Clin Immunol Pract; 2022 May; 10(5):1202-1216.e23. PubMed ID: 34990866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database.
    Cutroneo PM; Arzenton E; Furci F; Scapini F; Bulzomì M; Luxi N; Caminati M; Senna G; Moretti U; Trifirò G
    BioDrugs; 2024 May; 38(3):425-448. PubMed ID: 38489062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.
    Katsaounou P; Buhl R; Brusselle G; Pfister P; Martínez R; Wahn U; Bousquet J
    Respir Med; 2019 Apr; 150():51-62. PubMed ID: 30961951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.
    Agache I; Beltran J; Akdis C; Akdis M; Canelo-Aybar C; Canonica GW; Casale T; Chivato T; Corren J; Del Giacco S; Eiwegger T; Firinu D; Gern JE; Hamelmann E; Hanania N; Mäkelä M; Hernández-Martín I; Nair P; O'Mahony L; Papadopoulos NG; Papi A; Park HS; Pérez de Llano L; Posso M; Rocha C; Quirce S; Sastre J; Shamji M; Song Y; Steiner C; Schwarze J; Alonso-Coello P; Palomares O; Jutel M
    Allergy; 2020 May; 75(5):1023-1042. PubMed ID: 32034960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biologics in allergic rhinitis.
    Bayar Muluk N; Cingi C
    Eur Rev Med Pharmacol Sci; 2023 Oct; 27(5 Suppl):43-52. PubMed ID: 37869947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Smaller Differences in the Comparative Effectiveness of Biologics in Reducing Asthma-Related Hospitalizations Compared With Overall Exacerbations.
    Akenroye A; Marshall J; Simon AL; Hague C; Costa R; Jamal-Allial A; McMahill-Walraven CN; Haffenreffer K; Han A; Wu AC
    J Allergy Clin Immunol Pract; 2024 Jun; 12(6):1568-1574.e2. PubMed ID: 38431251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab.
    Ridolo E; Pucciarini F; Nizi MC; Makri E; Kihlgren P; Panella L; Incorvaia C
    Hum Vaccin Immunother; 2020 Oct; 16(10):2349-2356. PubMed ID: 32401603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma.
    Bateman ED; Khan AH; Xu Y; Guyot P; Chao J; Kamat S; Rowe P; Burnett H; Msihid J; Weinreich D; Pavord ID
    Respir Med; 2022 Jan; 191():105991. PubMed ID: 35090688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study.
    Albers FC; Müllerová H; Gunsoy NB; Shin JY; Nelsen LM; Bradford ES; Cockle SM; Suruki RY
    J Asthma; 2018 Feb; 55(2):152-160. PubMed ID: 28622052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Impact of Asthma Biologics: A Nationwide US Claim-Based Analysis.
    Al-Shaikhly T; Norris MR; Dennis EH; Liu G; Craig TJ
    J Allergy Clin Immunol Pract; 2024 Jun; 12(6):1558-1567. PubMed ID: 38423294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Biologics in Patients with Allergic Severe Asthma, Overall and by Blood Eosinophil Count: A Literature Review.
    Bernstein JA; Llanos JP; Hunter G; Martin N; Ambrose CS
    Adv Ther; 2023 Nov; 40(11):4721-4740. PubMed ID: 37698716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biologics for oral corticosteroid-dependent asthma.
    Yılmaz İ
    Allergy Asthma Proc; 2020 May; 41(3):151-157. PubMed ID: 32375958
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparison of Long-term Response and Remission to Omalizumab and Anti-IL-5/IL-5R Using Different Criteria in a Real-life Cohort of Severe Asthma Patients.
    Valverde-Monge M; Sánchez-Carrasco P; Betancor D; Barroso B; Rodrigo-Muñoz JM; Mahillo-Fernández I; Arismendi E; Bobolea I; Cárdaba B; Cruz MJ; Del Pozo V; Domínguez-Ortega J; González-Barcala FJ; Olaguibel JM; Luna-Porta JA; Martínez-Rivera C; Mullol J; Muñoz X; Peleteiro-Pedraza L; Picado Valles C; Plaza V; Quirce S; Rial MJ; Soto-Retes L; Valero A; Sastre J
    Arch Bronconeumol; 2024 Jan; 60(1):23-32. PubMed ID: 38042707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical characteristics of complete responders versus non-complete responders to omalizumab, benralizumab and mepolizumab in patients with severe asthma: a long-term retrospective analysis.
    Basagaña M; Martínez-Rivera C; Padró C; Garcia-Olivé I; Martínez-Colls M; Navarro J; Pardo L; Cruz P; Cardona Peitx G; Carabias L; Roger A; Abad J; Rosell A
    Ann Med; 2024 Dec; 56(1):2317356. PubMed ID: 38364218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lower Use of Biologics for the Treatment of Asthma in Publicly Insured Individuals.
    Akenroye AT; Heyward J; Keet C; Alexander GC
    J Allergy Clin Immunol Pract; 2021 Nov; 9(11):3969-3976. PubMed ID: 33556592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and economic burden of severe asthma among US patients treated with biologic therapies.
    Reibman J; Tan L; Ambrose C; Chung Y; Desai P; Llanos JP; Moynihan M; Tkacz J
    Ann Allergy Asthma Immunol; 2021 Sep; 127(3):318-325.e2. PubMed ID: 33775904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to Biologics and Clinical Remission in the Adult German Asthma Net Severe Asthma Registry Cohort.
    Milger K; Suhling H; Skowasch D; Holtdirk A; Kneidinger N; Behr J; Timmermann H; Schulz C; Schmidt O; Ehmann R; Hamelmann E; Idzko M; Taube C; Lommatzsch M; Buhl R; Korn S
    J Allergy Clin Immunol Pract; 2023 Sep; 11(9):2701-2712.e2. PubMed ID: 37301433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological treatments in childhood asthma.
    Nieto-García A; Nieto-Cid M; Mazón-Ramos Á
    Curr Opin Allergy Clin Immunol; 2024 Jun; 24(3):114-121. PubMed ID: 38567842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prior authorization delays biologic initiation and is associated with a risk of asthma exacerbations.
    Dudiak GJ; Popyack J; Grimm C; Tyson S; Solic J; Ishmael FT
    Allergy Asthma Proc; 2021 Jan; 42(1):65-71. PubMed ID: 33404389
    [No Abstract]   [Full Text] [Related]  

  • 20. [THE OVERLAPPING ELIGIBILITY FOR BIOLOGICS IN PATIENTS WITH SEVERE ASTHMA AND PHENOTYPES].
    Ito A; Miyoshi S; Toyota H; Suzuki Y; Uehara Y; Hattori S; Takeshita Y; Sakasegawa H; Kuramochi M; Kobayashi K; Sugimoto N; Nagase H
    Arerugi; 2022; 71(3):210-220. PubMed ID: 35569943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.